<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00422292</url>
  </required_header>
  <id_info>
    <org_study_id>MTA37</org_study_id>
    <nct_id>NCT00422292</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers</brief_title>
  <official_title>An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a modified single-blind, randomized, parallel-group, comparative, multicenter study
      to test Menactra vaccine in toddlers.

      Primary Objectives:

        -  To evaluate the antibody responses induced by Measles, Mumps, Rubella, and Varicella
           (MMRV) vaccine when administered alone or concomitantly with Menactra vaccine.

        -  To evaluate the antibody responses induced by Pneumococcal Conjugated Vaccine (PCV) when
           administered alone or concomitantly with Menactra vaccine.

      Observational Objectives:

      Safety - To describe the safety profile throughout the course of the study from Day 0 up to 6
      months after the last study vaccination[s]) in subjects in the study groups.

      Immunogenicity:

      - To describe the antibody responses to meningococcal serogroups A, C, Y, and W-135, 30 days
      after the first and second Menactra vaccine administration in a subset of subjects in the
      first study group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      No meningococcal vaccine is presently licensed for the population aged &lt; 2 years in the US,
      establishing the effectiveness of a quadrivalent polysaccharide conjugate vaccine against
      invasive meningococcal disease in children aged &lt; 2 years would address this important,
      currently unmet public health need.

      At enrollment, each 9-month old subject will be randomly assigned to a study group and
      vaccinated. A second vaccination will be administered at 12 months of age. Subjects will
      provide one blood sample during the trial.

      Twelve-month old subjects will also be vaccinated with routine pediatric vaccines and provide
      one blood sample 30 days after vaccinations in the control group
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measles, Mumps, Rubella, and Varicella (MMRV) Antibody Values in Participants Who Received MMRV Vaccine (Groups 2 and 4 Only)</measure>
    <time_frame>Day 30 after the 12-month vaccination</time_frame>
    <description>Percentage of participants who had a concentration of ≥ 300 mIU/mL in the enzyme-linked immunosorbent assay (ELISA) or ≥ 120 mIU/mL in the neutralization when the ELISA concentration was less than 300 mIU/mL - for measles; ≥ 500 U/mL (ELISA) or ≥ 60 (1/dil) in the neutralization assay when the ELISA concentration was less than 500 mIU/mL - for mumps; ≥ 10 IU/mL (ELISA) - for Rubella; and ≥ 300 mIU/mL (ELISA) or ≥ 4 (1/dil) Fluorescent antibody to membrane antigen (FAMA) when the ELISA concentration was less than 300 mIU/mL - for varicella.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentrations (GMCs) of Anti-Pneumococcal Antibodies After Pneumococcal Conjugated Vaccine (PCV) in Groups 3 and 4</measure>
    <time_frame>Day 30 after the 12-month vaccination</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Percentage of Participants With Anti-Pneumococcal Concentrations ≥ 0.35 μg/mL After Pneumococcal Conjugate Vaccine (PCV) in Group 3 and Group 4</measure>
    <time_frame>Day 30 after 12-month vaccination</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants Reporting a Solicited Injection Site and Systemic Reactions After Menactra® Vaccination at 9 Months of Age</measure>
    <time_frame>Days 0 to 7 after vaccination</time_frame>
    <description>Solicited injection site reactions: Injection site tenderness, injection site erythema, and injection site swelling.
Solicited systemic reactions: Fever (temperature), vomiting, crying abnormal, drowsiness, appetite lost, and irritability.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants With Solicited Injection Site and Systemic Reactions After Vaccination at 12 Months of Age</measure>
    <time_frame>Days 0 to 7 after vaccination</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1664</enrollment>
  <condition>Meningococcal Meningitis</condition>
  <condition>Measles</condition>
  <condition>Mumps</condition>
  <condition>Rubella</condition>
  <condition>Varicella</condition>
  <arm_group>
    <arm_group_label>Menactra® at 9 and 12 Months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will received Menactra® vaccination at 9 and 12 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Menactra® at 9 Months and Menactra® + MMRV at 12 Months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Menactra® at 9 months of age and Menactra® plus measles, mumps, rubella, varicella (MMRV) vaccine at 12 months of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Menactra® at 9 Months and Menactra® + PCV at 12 Months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Menactra® at 9 months of age and Menactra® plus pneumococcal conjugate vaccine (PCV) at 12 months of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MMRV + PCV at 12 Months</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who received no vaccination at 9 months of age and measles, mumps, rubella, varicella (MMRV) vaccine plus pneumococcal conjugate vaccine (PCV) at 12 months of age</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal Polysaccharide Diphtheria Conjugate Vaccine</intervention_name>
    <description>0.5 mL dose, intramuscular (IM)</description>
    <arm_group_label>Menactra® at 9 and 12 Months</arm_group_label>
    <other_name>Menactra®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal Polysaccharide Diphtheria Conjugate Vaccine</intervention_name>
    <description>0.5 mL dose, IM</description>
    <arm_group_label>Menactra® at 9 Months and Menactra® + MMRV at 12 Months</arm_group_label>
    <other_name>Menactra®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal Polysaccharide Diphtheria Conjugate Vaccine</intervention_name>
    <description>0.5 Ml dose, IM</description>
    <arm_group_label>Menactra® at 9 Months and Menactra® + PCV at 12 Months</arm_group_label>
    <other_name>Menactra®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Measles, Mumps, Rubella and Varicella</intervention_name>
    <description>0.5 mL dose, SC</description>
    <arm_group_label>MMRV + PCV at 12 Months</arm_group_label>
    <other_name>ProQuad®</other_name>
    <other_name>M-M-R®II</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  Healthy, as determined by medical history and physical examination

          -  Aged 9 months (249 to 291 days) for Groups 1, 2, and 3 or aged 12 months (365 to 386
             days) for Group 4 at the time of enrollment

          -  The parent or legal guardian has signed and dated the Institutional Review Board
             (IRB)-approved informed consent form.

        Exclusion Criteria :

          -  Serious acute or chronic disease (e.g., cardiac, renal, metabolic, rheumatologic,
             psychiatric, hematologic, autoimmune disorders, diabetes, atopic conditions,
             congenital defects, convulsions, encephalopathy, blood dyscrasias, leukemia, lymphomas
             of any type, or other malignant neoplasms affecting the bone marrow or lymphatic
             system, acute untreated tuberculosis) that could interfere with trial conduct or
             completion

          -  Known or suspected impairment of immunologic function

          -  Acute medical illness within the last 72 hours or a temperature ≥ 100.4ºF (≥38.0ºC) at
             the time of enrollment.

          -  History of documented invasive meningococcal disease or previous meningococcal
             vaccination.

          -  Known human immunodeficiency virus (HIV), hepatitis B, or hepatitis C seropositivity
             as reported by the parent or legal guardian

          -  Received either immune globulin or other blood products within the last 3 months, or
             received injected or oral corticosteroids, or other immunomodulator therapy within 6
             weeks of the study vaccines. Individuals on a tapering dose schedule of oral steroids
             lasting &lt; 7 days and individuals (e.g., asthmatics) on a short schedule of oral
             steroids lasting 3 to 4 days may be included in the trial as long as they have not
             received more than one course within the last two weeks prior to enrollment. Topical
             steroids are not included in this exclusion criterion.

          -  Anticipated to receive oral or injected antibiotic therapy within the 72 hours prior
             to any blood draw. Topical antibiotics and antibiotic drops are not included in this
             exclusion criterion.

          -  Suspected or known hypersensitivity to any of the vaccine components or history of a
             life-threatening reaction to the study vaccines or a vaccine containing the same
             substances. For ProQuad vaccine recipients, this includes a hypersensitivity to
             gelatin or a history of anaphylactic reactions to neomycin.

          -  Thrombocytopenia or a bleeding disorder contraindicating intramuscular (IM)
             vaccination.

          -  Parent or legal guardian unable or unwilling to comply with the study procedures

          -  Participation in another interventional clinical trial in the 30 days preceding
             enrollment or planned participation in another clinical trial involving the
             investigation of a drug, vaccine, medical procedure, or medical device during the
             subject's trial period.

          -  Diagnosed with any condition, which, in the opinion of the investigator, would pose a
             health risk to the subject or interfere with the evaluation of the vaccine

          -  Received any vaccine in the 30-day period prior to receipt of the study vaccines, or
             scheduled to receive any vaccination other than influenza vaccination and
             hyposensitization therapy in the 30-day period after receipt of the study vaccines.
             Hyposensitization therapy and influenza vaccination may be received up to two weeks
             before or two weeks after receiving the study vaccines. Subjects should not have
             received their fourth dose of Pneumococcal conjugate vaccine (PCV) or Haemophilus
             influenzae type b (Hib) vaccine or their first dose of Measles, mumps, rubella,
             varicella (MMRV) vaccine before enrollment or been scheduled to receive these vaccines
             outside of the study-specified visits.

          -  Personal or family history of Guillain-Barré Syndrome (GBS)

          -  History of seizures, including febrile seizures, or any other neurologic disorder

          -  Known hypersensitivity to dry natural rubber latex.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Months</minimum_age>
    <maximum_age>12 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tuscaloosa</city>
        <state>Alabama</state>
        <zip>35401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atascadero</city>
        <state>California</state>
        <zip>93422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93726</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95823</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Viera</city>
        <state>Florida</state>
        <zip>32940</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dalton</city>
        <state>Georgia</state>
        <zip>30721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tifton</city>
        <state>Georgia</state>
        <zip>31794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woodstock</city>
        <state>Georgia</state>
        <zip>30189</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fishers</city>
        <state>Indiana</state>
        <zip>46038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dubuque</city>
        <state>Iowa</state>
        <zip>52001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dubuque</city>
        <state>Iowa</state>
        <zip>52002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bossier City</city>
        <state>Louisiana</state>
        <zip>71111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perry Hall</city>
        <state>Maryland</state>
        <zip>21128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woburn</city>
        <state>Massachusetts</state>
        <zip>01801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Niles</city>
        <state>Michigan</state>
        <zip>49120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stevensville</city>
        <state>Michigan</state>
        <zip>49127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bridgeton</city>
        <state>Missouri</state>
        <zip>63044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Charles</city>
        <state>Missouri</state>
        <zip>63303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <zip>68123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Vista</city>
        <state>Nebraska</state>
        <zip>68128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Whitehouse Station</city>
        <state>New Jersey</state>
        <zip>08889</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fishkill</city>
        <state>New York</state>
        <zip>12524</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hopewell Junction</city>
        <state>New York</state>
        <zip>12533</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ithaca</city>
        <state>New York</state>
        <zip>14850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boone</city>
        <state>North Carolina</state>
        <zip>28607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clyde</city>
        <state>North Carolina</state>
        <zip>28721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Independence</city>
        <state>Ohio</state>
        <zip>44131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Strongsville</city>
        <state>Ohio</state>
        <zip>44136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Harleysville</city>
        <state>Pennsylvania</state>
        <zip>19438</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sellersville</city>
        <state>Pennsylvania</state>
        <zip>18960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wexford</city>
        <state>Pennsylvania</state>
        <zip>15090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clarksville</city>
        <state>Tennessee</state>
        <zip>37043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lehi</city>
        <state>Utah</state>
        <zip>84043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pleasant Grove</city>
        <state>Utah</state>
        <zip>84062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <zip>84604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springville</city>
        <state>Utah</state>
        <zip>84663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. George</city>
        <state>Utah</state>
        <zip>84790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Urem</city>
        <state>Utah</state>
        <zip>84057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Midlothian</city>
        <state>Virginia</state>
        <zip>23113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntington</city>
        <state>West Virginia</state>
        <zip>25701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <zip>00918</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2007</study_first_submitted>
  <study_first_submitted_qc>January 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2007</study_first_posted>
  <results_first_submitted>May 10, 2011</results_first_submitted>
  <results_first_submitted_qc>May 10, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 2, 2011</results_first_posted>
  <disposition_first_submitted>March 31, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>March 31, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 2, 2010</disposition_first_posted>
  <last_update_submitted>April 12, 2016</last_update_submitted>
  <last_update_submitted_qc>April 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Menactra vaccine</keyword>
  <keyword>Meningococcal meningitis</keyword>
  <keyword>Measles</keyword>
  <keyword>Mumps</keyword>
  <keyword>Rubella</keyword>
  <keyword>Varicella vaccines</keyword>
  <keyword>Haemophilus influenzae type b</keyword>
  <keyword>Pneumococcal conjugate vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Measles</mesh_term>
    <mesh_term>Chickenpox</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Rubella</mesh_term>
    <mesh_term>Meningitis, Meningococcal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from 15 January 2007 to 16 March 2008 in 92 clinical centers in the US.</recruitment_details>
      <pre_assignment_details>A total of 2289 participants who met the inclusion and exclusion criteria were enrolled and vaccinated; 1643 were included in the final analyses presented.
625 participants that got ActHIB as part of their 12 month study vaccinations prior to Protocol Amendment 2 approval were excluded from all analyses and presented in a separate report.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1: Menactra® at 9 and 12 Months</title>
          <description>Participants who received only Menactra® vaccination at 9 and 12 months of age</description>
        </group>
        <group group_id="P2">
          <title>Group 2: Menactra® at 9 Months; Menactra® + MMRV at 12 Months</title>
          <description>Participants who received Menactra® at 9 months of age and Menactra® plus measles, mumps, rubella, varicella (MMRV or MMR+V) vaccine at 12 months of age</description>
        </group>
        <group group_id="P3">
          <title>Group 3: Menactra® at 9 Months; Menactra® + PCV at 12 Months</title>
          <description>Participants who received Menactra® at 9 months of age and Menactra® plus pneumococcal conjugate vaccine (PCV) at 12 months of age</description>
        </group>
        <group group_id="P4">
          <title>Group 4: MMRV + PCV at 12 Months</title>
          <description>Participants who received no vaccination at 9 months of age and measles, mumps, rubella, varicella (MMRV) vaccine plus pneumococcal conjugate vaccine (PCV) at 12 months of age</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="257"/>
                <participants group_id="P2" count="664"/>
                <participants group_id="P3" count="246"/>
                <participants group_id="P4" count="476"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="239"/>
                <participants group_id="P2" count="598"/>
                <participants group_id="P3" count="224"/>
                <participants group_id="P4" count="452"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Serious adverse events</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1: Menactra® at 9 and 12 Months</title>
          <description>Participants who received only Menactra® vaccination at 9 and 12 months of age</description>
        </group>
        <group group_id="B2">
          <title>Group 2: Menactra® at 9 Months; Menactra® + MMRV at 12 Months</title>
          <description>Participants who received Menactra® at 9 months of age and Menactra® plus measles, mumps, rubella, varicella (MMRV or MMR+V) vaccine at 12 months of age</description>
        </group>
        <group group_id="B3">
          <title>Group 3: Menactra® at 9 Months; Menactra® + PCV at 12 Months</title>
          <description>Participants who received Menactra® at 9 months of age and Menactra® plus pneumococcal conjugate vaccine (PCV) at 12 months of age</description>
        </group>
        <group group_id="B4">
          <title>Group 4: MMRV + PCV at 12 Months</title>
          <description>Participants who received no vaccination at 9 months of age and measles, mumps, rubella, varicella (MMRV) vaccine plus pneumococcal conjugate vaccine (PCV) at 12 months of age</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="257"/>
            <count group_id="B2" value="664"/>
            <count group_id="B3" value="246"/>
            <count group_id="B4" value="476"/>
            <count group_id="B5" value="1643"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="257"/>
                    <measurement group_id="B2" value="664"/>
                    <measurement group_id="B3" value="246"/>
                    <measurement group_id="B4" value="476"/>
                    <measurement group_id="B5" value="1643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="283.4" spread="11.3"/>
                    <measurement group_id="B2" value="283.0" spread="11.3"/>
                    <measurement group_id="B3" value="282.8" spread="10.3"/>
                    <measurement group_id="B4" value="374.8" spread="8.6"/>
                    <measurement group_id="B5" value="283.4" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="349"/>
                    <measurement group_id="B3" value="118"/>
                    <measurement group_id="B4" value="231"/>
                    <measurement group_id="B5" value="817"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                    <measurement group_id="B2" value="315"/>
                    <measurement group_id="B3" value="128"/>
                    <measurement group_id="B4" value="245"/>
                    <measurement group_id="B5" value="826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="257"/>
                    <measurement group_id="B2" value="664"/>
                    <measurement group_id="B3" value="246"/>
                    <measurement group_id="B4" value="476"/>
                    <measurement group_id="B5" value="1643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Measles, Mumps, Rubella, and Varicella (MMRV) Antibody Values in Participants Who Received MMRV Vaccine (Groups 2 and 4 Only)</title>
        <description>Percentage of participants who had a concentration of ≥ 300 mIU/mL in the enzyme-linked immunosorbent assay (ELISA) or ≥ 120 mIU/mL in the neutralization when the ELISA concentration was less than 300 mIU/mL - for measles; ≥ 500 U/mL (ELISA) or ≥ 60 (1/dil) in the neutralization assay when the ELISA concentration was less than 500 mIU/mL - for mumps; ≥ 10 IU/mL (ELISA) - for Rubella; and ≥ 300 mIU/mL (ELISA) or ≥ 4 (1/dil) Fluorescent antibody to membrane antigen (FAMA) when the ELISA concentration was less than 300 mIU/mL - for varicella.</description>
        <time_frame>Day 30 after the 12-month vaccination</time_frame>
        <population>Antibody responses were evaluated in the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Menactra® at 9 and 12 Months</title>
            <description>Participants who received only Menactra® vaccination at 9 and 12 months of age</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Menactra® at 9 Months; Menactra® + MMRV at 12 Months</title>
            <description>Participants who received Menactra® at 9 months of age and Menactra® plus measles, mumps, rubella, varicella (MMRV or MMR+V) vaccine at 12 months of age</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Menactra® at 9 Months; Menactra® + PCV at 12 Months</title>
            <description>Participants who received Menactra® at 9 months of age and Menactra® plus pneumococcal conjugate vaccine (PCV) at 12 months of age</description>
          </group>
          <group group_id="O4">
            <title>Group 4: MMRV + PCV at 12 Months</title>
            <description>Participants who received no vaccination at 9 months of age and measles, mumps, rubella, varicella (MMRV) vaccine plus pneumococcal conjugate vaccine (PCV) at 12 months of age</description>
          </group>
        </group_list>
        <measure>
          <title>Measles, Mumps, Rubella, and Varicella (MMRV) Antibody Values in Participants Who Received MMRV Vaccine (Groups 2 and 4 Only)</title>
          <description>Percentage of participants who had a concentration of ≥ 300 mIU/mL in the enzyme-linked immunosorbent assay (ELISA) or ≥ 120 mIU/mL in the neutralization when the ELISA concentration was less than 300 mIU/mL - for measles; ≥ 500 U/mL (ELISA) or ≥ 60 (1/dil) in the neutralization assay when the ELISA concentration was less than 500 mIU/mL - for mumps; ≥ 10 IU/mL (ELISA) - for Rubella; and ≥ 300 mIU/mL (ELISA) or ≥ 4 (1/dil) Fluorescent antibody to membrane antigen (FAMA) when the ELISA concentration was less than 300 mIU/mL - for varicella.</description>
          <population>Antibody responses were evaluated in the per-protocol population.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="498"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="399"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Measles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O4" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mumps</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O4" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rubella</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="93"/>
                    <measurement group_id="O4" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="93"/>
                    <measurement group_id="O4" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentrations (GMCs) of Anti-Pneumococcal Antibodies After Pneumococcal Conjugated Vaccine (PCV) in Groups 3 and 4</title>
        <time_frame>Day 30 after the 12-month vaccination</time_frame>
        <population>Geometric Mean Concentrations (GMCs) were determined in the per-protocol population Group 3 and Group 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Menactra® at 9 and 12 Months</title>
            <description>Participants who received only Menactra® vaccination at 9 and 12 months of age</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Menactra® at 9 Months; Menactra® + MMRV at 12 Months</title>
            <description>Participants who received Menactra® at 9 months of age and Menactra® plus measles, mumps, rubella, varicella (MMRV or MMR+V) vaccine at 12 months of age</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Menactra® at 9 Months; Menactra® + PCV at 12 Months</title>
            <description>Participants who received Menactra® at 9 months of age and Menactra® plus pneumococcal conjugate vaccine (PCV) at 12 months of age</description>
          </group>
          <group group_id="O4">
            <title>Group 4: MMRV + PCV at 12 Months</title>
            <description>Participants who received no vaccination at 9 months of age and measles, mumps, rubella, varicella (MMRV) vaccine plus pneumococcal conjugate vaccine (PCV) at 12 months of age</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations (GMCs) of Anti-Pneumococcal Antibodies After Pneumococcal Conjugated Vaccine (PCV) in Groups 3 and 4</title>
          <population>Geometric Mean Concentrations (GMCs) were determined in the per-protocol population Group 3 and Group 4.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="191"/>
                <count group_id="O4" value="399"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1.82" lower_limit="1.62" upper_limit="2.05"/>
                    <measurement group_id="O4" value="3.33" lower_limit="3.06" upper_limit="3.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="5.40" lower_limit="4.79" upper_limit="6.09"/>
                    <measurement group_id="O4" value="10.8" lower_limit="9.89" upper_limit="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="2.06" lower_limit="1.84" upper_limit="2.30"/>
                    <measurement group_id="O4" value="3.57" lower_limit="3.29" upper_limit="3.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="6.73" lower_limit="5.95" upper_limit="7.60"/>
                    <measurement group_id="O4" value="10.5" lower_limit="9.65" upper_limit="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1.58" lower_limit="1.43" upper_limit="1.75"/>
                    <measurement group_id="O4" value="2.91" lower_limit="2.66" upper_limit="3.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="2.50" lower_limit="2.24" upper_limit="2.78"/>
                    <measurement group_id="O4" value="4.03" lower_limit="3.74" upper_limit="4.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="4.62" lower_limit="4.06" upper_limit="5.25"/>
                    <measurement group_id="O4" value="7.03" lower_limit="6.39" upper_limit="7.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With Anti-Pneumococcal Concentrations ≥ 0.35 μg/mL After Pneumococcal Conjugate Vaccine (PCV) in Group 3 and Group 4</title>
        <time_frame>Day 30 after 12-month vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Menactra® at 9 and 12 Months</title>
            <description>Participants who received only Menactra® vaccination at 9 and 12 months of age</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Menactra® at 9 Months; Menactra® + MMRV at 12 Months</title>
            <description>Participants who received Menactra® at 9 months of age and Menactra® plus measles, mumps, rubella, varicella (MMRV or MMR+V) vaccine at 12 months of age</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Menactra® at 9 Months; Menactra® + PCV at 12 Months</title>
            <description>Participants who received Menactra® at 9 months of age and Menactra® plus pneumococcal conjugate vaccine (PCV) at 12 months of age</description>
          </group>
          <group group_id="O4">
            <title>Group 4: MMRV + PCV at 12 Months</title>
            <description>Participants who received no vaccination at 9 months of age and measles, mumps, rubella, varicella (MMRV) vaccine plus pneumococcal conjugate vaccine (PCV) at 12 months of age</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Anti-Pneumococcal Concentrations ≥ 0.35 μg/mL After Pneumococcal Conjugate Vaccine (PCV) in Group 3 and Group 4</title>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="191"/>
                <count group_id="O4" value="399"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="98"/>
                    <measurement group_id="O4" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="98"/>
                    <measurement group_id="O4" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting a Solicited Injection Site and Systemic Reactions After Menactra® Vaccination at 9 Months of Age</title>
        <description>Solicited injection site reactions: Injection site tenderness, injection site erythema, and injection site swelling.
Solicited systemic reactions: Fever (temperature), vomiting, crying abnormal, drowsiness, appetite lost, and irritability.</description>
        <time_frame>Days 0 to 7 after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Menactra® at 9 and 12 Months</title>
            <description>Participants who received only Menactra® vaccination at 9 and 12 months of age</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Menactra® at 9 Months; Menactra® + MMRV at 12 Months</title>
            <description>Participants who received Menactra® at 9 months of age and Menactra® plus measles, mumps, rubella, varicella (MMRV or MMR+V) vaccine at 12 months of age</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Menactra® at 9 Months; Menactra® + PCV at 12 Months</title>
            <description>Participants who received Menactra® at 9 months of age and Menactra® plus pneumococcal conjugate vaccine (PCV) at 12 months of age</description>
          </group>
          <group group_id="O4">
            <title>Group 4: MMRV + PCV at 12 Months</title>
            <description>Participants who received no vaccination at 9 months of age and measles, mumps, rubella, varicella (MMRV) vaccine plus pneumococcal conjugate vaccine (PCV) at 12 months of age</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting a Solicited Injection Site and Systemic Reactions After Menactra® Vaccination at 9 Months of Age</title>
          <description>Solicited injection site reactions: Injection site tenderness, injection site erythema, and injection site swelling.
Solicited systemic reactions: Fever (temperature), vomiting, crying abnormal, drowsiness, appetite lost, and irritability.</description>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="616"/>
                <count group_id="O3" value="246"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Solicited Injection Site Reacton</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Tenderness (Cries when limb is moved)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Erythema (≥ 2.0 in)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling (≥ 2.0 in)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Systemic Reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever (&gt; 103.1 ºF or &gt; 39.5 ºC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Crying Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Crying Abnormal (&gt; 3 hours)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability (Inconsolable)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness (Sleeps most of time)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Appetite Lost</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Appetite Lost (Refuses ≥ 3 feeds/meals)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With Solicited Injection Site and Systemic Reactions After Vaccination at 12 Months of Age</title>
        <time_frame>Days 0 to 7 after vaccination</time_frame>
        <population>Solicited Injection Site and Systemic Reactions were assessed in the intend-to-treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Menactra® at 9 and 12 Months</title>
            <description>Participants who received only Menactra® vaccination at 9 and 12 months of age</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Menactra® at 9 Months; Menactra® + MMRV at 12 Months</title>
            <description>Participants who received Menactra® at 9 months of age and Menactra® plus measles, mumps, rubella, varicella (MMRV or MMR+V) vaccine at 12 months of age</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Menactra® at 9 Months; Menactra® + PCV at 12 Months</title>
            <description>Participants who received Menactra® at 9 months of age and Menactra® plus pneumococcal conjugate vaccine (PCV) at 12 months of age</description>
          </group>
          <group group_id="O4">
            <title>Group 4: MMRV + PCV at 12 Months</title>
            <description>Participants who received no vaccination at 9 months of age and measles, mumps, rubella, varicella (MMRV) vaccine plus pneumococcal conjugate vaccine (PCV) at 12 months of age</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Solicited Injection Site and Systemic Reactions After Vaccination at 12 Months of Age</title>
          <population>Solicited Injection Site and Systemic Reactions were assessed in the intend-to-treat population.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="572"/>
                <count group_id="O3" value="246"/>
                <count group_id="O4" value="476"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Solicited Injection Site Reaction - Menactra</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="57"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="51"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Tenderness (Cries when limb is moved)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Erythema (≥ 2.0 in)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling (≥ 2.0 in)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Injection Site Reaction - MMRV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Tenderness (Cries when limb is moved)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Erythema (≥ 2.0 in)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling (≥ 2.0 in)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Injection Site Reaction - PCV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Tenderness (Cries when limb is moved)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Erythema (≥ 2.0 in)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling (≥ 2.0 in)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Systemic Reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="69"/>
                    <measurement group_id="O4" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever (&gt; 103.1 ºF or &gt; 39.5 ºC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Crying Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Crying Abnormal (&gt; 3 hours)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="60"/>
                    <measurement group_id="O4" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability (Inconsolable)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness (Sleeps most of time)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Appetite Lost</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Appetite Lost (Refuses ≥ 3 feeds/meals)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected for 6 months after the last vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1: Menactra® at 9 and 12 Months</title>
          <description>Participants who received only Menactra® vaccination at 9 and 12 months of age</description>
        </group>
        <group group_id="E2">
          <title>Group 2: Menactra® at 9 Months; Menactra® + MMRV at 12 Month</title>
          <description>Participants who received Menactra® at 9 months of age and Menactra® plus measles, mumps, rubella, varicella (MMRV or MMR+V) vaccine at 12 months of age</description>
        </group>
        <group group_id="E3">
          <title>Group 3: Menactra® at 12 Months; Menactra® + PCV at 12 Months</title>
          <description>Participants who received Menactra® at 9 months of age and Menactra® plus pneumococcal conjugate vaccine (PCV) at 12 months of age</description>
        </group>
        <group group_id="E4">
          <title>Group 4: MMRV + PCV at 12 Months</title>
          <description>Participants who received no vaccination at 9 months of age and measles, mumps, rubella, varicella (MMRV) vaccine plus pneumococcal conjugate vaccine (PCV) at 12 months of age</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="616"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="246"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital spinal cord anomaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="616"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="246"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Infected Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Kawasaki's diseas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Periumbilical abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Staphylococcal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Closed head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Foreign body trauma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Craniosynostosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Autism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="257"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Myoclonic epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Bronchial hyperactivity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="257"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.0</frequency_threshold>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="185" subjects_at_risk="664"/>
                <counts group_id="E3" subjects_affected="77" subjects_at_risk="246"/>
                <counts group_id="E4" subjects_affected="148" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="257"/>
                <counts group_id="E2" events="42" subjects_affected="38" subjects_at_risk="664"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="246"/>
                <counts group_id="E4" events="33" subjects_affected="29" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="257"/>
                <counts group_id="E2" events="32" subjects_affected="27" subjects_at_risk="664"/>
                <counts group_id="E3" events="20" subjects_affected="17" subjects_at_risk="246"/>
                <counts group_id="E4" events="17" subjects_affected="15" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="257"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="664"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="246"/>
                <counts group_id="E4" events="51" subjects_affected="48" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="257"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="664"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="246"/>
                <counts group_id="E4" events="11" subjects_affected="10" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="25" subjects_affected="24" subjects_at_risk="257"/>
                <counts group_id="E2" events="52" subjects_affected="52" subjects_at_risk="664"/>
                <counts group_id="E3" events="22" subjects_affected="22" subjects_at_risk="246"/>
                <counts group_id="E4" events="20" subjects_affected="20" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="257"/>
                <counts group_id="E2" events="51" subjects_affected="50" subjects_at_risk="664"/>
                <counts group_id="E3" events="26" subjects_affected="25" subjects_at_risk="246"/>
                <counts group_id="E4" events="19" subjects_affected="19" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="257"/>
                <counts group_id="E2" events="29" subjects_affected="28" subjects_at_risk="664"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="246"/>
                <counts group_id="E4" events="16" subjects_affected="16" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="257"/>
                <counts group_id="E2" events="27" subjects_affected="25" subjects_at_risk="664"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="246"/>
                <counts group_id="E4" events="22" subjects_affected="22" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

